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Abstract
Background: This report presents a novel case of bilateral neuroretinitis and anterior uveitis in a patient receiving
ipilimumab treatment for metastatic cutaneous melanoma and summarizes the literature regarding treatment
options for patients with ipilimumab-related ocular immune-related adverse events.
Findings: The medical chart was reviewed, a literature search was performed, and the results were summarized. For
the case presented here, in addition to discontinuation of ipilimumab, combined topical and oral corticosteroid
therapy provided visual recovery and resolution of ocular inflammation over 2 months. Review of the literature
identified that the majority of reported patients required treatment with oral corticosteroids for control of ocular
and periocular inflammation.
Conclusions: Ipilimumab-induced ocular inflammation is a rare adverse immune event. This case, in conjunction
with the current literature, suggests that in the setting of severe ocular inflammation, treatment with both topical
and oral corticosteroids are typically required for management and preservation of good visual function.
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Introduction
Ipilimumab is a monoclonal antibody directed against cyto-
toxic T-lymphocyte antigen 4 (CTLA4), a checkpoint mol-
ecule present on the surface of activated T-lymphocytes [1].
CTLA4 negatively regulates T-lymphocyte proliferation and
activation, and inhibitors of this molecule are approved by
the Food and Drug Administration (FDA) as a treatment
for metastatic melanoma [2]. Treatment with ipilimumab
causes tumor regression as well as immune-related adverse
events (irAEs) in almost two thirds of patients. The most
common irAEs include dermatitis, enterocolitis, and hypo-
physitis and are dose related [3]. Management of these tox-
icities depends on the severity and can be stratified into
grades. In patients with clinically significant (stage 3 or 4)
or severe irAEs, ipilimumab therapy is typically discontin-
ued and systemic corticosteroids such as prednisone 1 to
2 mg/kg daily are given to control inflammation [4].
Ocular irAEs occur in less than 1 % of patients re-
ceiving ipilimumab treatment as compared to 44 % of
patients reporting diarrhea or colitis as a side effect [5].
Case reports have described a range of ocular involve-
ment including bilateral anterior uveitis, vitritis, and
papillitis [5–7]; choroiditis and serous retinal detach-
ments [8–10]; peripheral ulcerative keratitis (PUK) [7];
inflammatory orbitopathy [7, 11, 12]; choroidal neovascu-
larization (CNV) [13]; uveitis with a myasthenia gravis-
type syndrome [14]; and bilateral optic neuropathy [15].
This report describes neuroretinitis and anterior uveitis as
a novel ipilimumab ocular irAE.
Case report
A 44-year-old Hispanic male presented for evaluation of
bilateral ocular inflammation in the setting of treatment
with ipilimumab for metastatic cutaneous melanoma.
Two months prior to presentation, he had received his
third infusion with partial regression of his metastatic le-
sions. Subsequent to this dose, he began to experience sys-
temic inflammatory side effects from therapy including
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rash, diarrhea, fever, and persistent rectal abscesses requir-
ing treatment with a high-dose oral prednisone in addition
to cessation of ipilimumab therapy. While on a tapering
dose of oral prednisone (20-mg prednisone), he began to
experience ocular symptoms including metamorphopsias
in the right eye, scotoma in the left eye, bilateral eye pain,
redness, and photophobia. One week later on examination
with a comprehensive ophthalmologist, he was noted to
have anterior chamber inflammation and bilateral optic
nerve edema. An MRI of the brain was obtained, but it did
not identify any mass lesions. Topical therapy with pred-
nisolone acetate was initiated, and he was referred to the
uveitis service for further evaluation.
Upon presentation, he denied eye pain or redness but
reported persistent central scotoma in the left eye. Current
therapy included bilateral prednisolone acetate 1 % four
times daily, 0.2 % brimonidine tartrate-0.5 % timolol male-
ate ophthalmic solution twice daily, and 20 mg of oral
prednisone daily. His other systemic autoimmune symp-
toms were well controlled. He did not have a history of
prior autoimmune diseases and exposure to ticks or kit-
tens and had no headache, pain with eye movement, or
pulsatile tinnitus.
On examination, his visual acuity was 20/40-1 in the
right eye and 20/150 in the left eye. Intraocular pressures
were normal. Slit lamp examination revealed pigment on
the endothelium without keratic precipitates (KP) bilat-
erally as well as 1+ flare and 0.5+ cell in both the anterior
chambers. Rare cell was noted immediately posterior to
the lens without vitreous haze or posterior vitritis. Fundus
examination showed bilateral optic nerve edema with
Paton’s lines and macular edema (Fig. 1a, b, f ). In the
left eye, a splinter hemorrhage was noted on the super-
ior disc margin (Fig. 1c). The vessels were perfused
without sheathing or arteriovenous crossing changes.
The peripheral retina was unremarkable. Optical coher-
ence tomography (OCT) revealed significant bilateral
cystic intraretinal and subfoveal fluid (Fig. 1d, e).
Quantiferon testing and syphilis serology were negative,
and his oral prednisone was increased to 80 mg daily.
Topical prednisolone acetate was decreased to three times
daily, and 0.2 % brimonidine tartrate-0.5 % timolol male-
ate ophthalmic solution was continued in both eyes. At
one-week follow-up, his vision was 20/60 in the right eye
and 20/50 in the left eye. Fundus photos showed improv-
ing optic nerve edema bilaterally, decreased retinal folds,
and the initial development of a macular star in both eyes
(the left eye shown in Fig. 1g). Oral prednisone was ta-
pered by 10 mg per week down to 10 mg daily, and the
topical prednisolone acetate was tapered to once daily in
both eyes. Over the course of the next 3 weeks, his vision
steadily improved with resolution of the optic nerve and
Fig. 1 Ipilimumab-associated bilateral neuroretinitis. Presentation images showing disc edema with Paton’s lines of the a right and b left eyes.
c Higher magnification image of the left eye reveals a splinter hemorrhage on the superior temporal nerve. Spectral domain OCT images of
the d right and e left eyes reveal edema of the optic nerve and subfoveal and intraretinal fluid in both eyes. d–h Time course of images of
the left eye from presentation f to 1-week follow-up g to 1-month follow-up h showing resolution of optic nerve and macular edema with
development of a macular star
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retinal edema and subsequent development of a macular
star (Fig. 1h). Due to gastrointestinal upset while taking
10 mg of prednisone a day, the patient discontinued oral
corticosteroids without additional tapering and experi-
enced a flare of bilateral anterior uveitis which was treated
with 0.05 % topical difluprednate. No recurrence of the
neuroretinitis was noted. By the 2-month follow-up, vision
in both eyes improved to 20/25 and his anterior chamber
reaction stabilized at 1+ flare and rare cell while taking
prednisolone acetate four times a day. The patient was
then lost to follow-up.
Discussion
Treatment of ipilimumab-associated ocular irAEs depends
on the severity and location of inflammation and may be
influenced by concurrent therapy for other systemic com-
plications. In the largest case series of patients with
ipilimumab-associated ocular irAEs [7], 6/7 patients were
treated with oral corticosteroids alone or in conjunction
with topical corticosteroids. Oral corticosteroid treatment
was initiated specifically for control of ocular disease in the
four patients with orbital inflammation. In an additional of
two patients with anterior uveitis, systemic corticosteroids
were initiated for control of other inflammatory com-
plications [7]. Topical corticosteroid drops were added
in addition to ongoing systemic treatment for two pa-
tients with anterior uveitis and as sole therapy for the
patient with PUK. The authors also reviewed 15 previ-
ously published cases of ipilimumab-associated ocular
irAEs. They found that 9 of the 15 cases were treated
with systemic corticosteroids and 3 with topical cortico-
steroids alone. One patient with CNV was treated with
intravitreal ranibizumab without corticosteroids [13], one
patient with a myasthenia gravis-type syndrome was treated
with plasmapheresis [14], and one patient with conjunctiv-
itis was treated with topical lubrication [16]. Most patients
also had ipilimumab therapy withheld. Twelve of the 15
patients had resolution of their inflammation. The authors
concluded that ocular irAEs from ipilimumab resolve with
corticosteroid treatment often without sequelae. Subse-
quent to this review, a case of bilateral optic neuropathy
was described by Yeh and Francis that was treated with
topical therapy alone. In this case, anterior uveitis devel-
oped after the third round of ipilimumab therapy. His in-
flammation then evolved into bilateral optic nerve edema
with macular edema and decreased vision after the fourth
round of ipilimumab therapy. Oral therapy was declined
by the patient, and he was treated with topical prednisol-
one acetate every 2 hours. Anterior segment and optic
nerve inflammation resolved after 3 months, but optic
nerve pallor developed. Despite regaining 20/25 central vi-
sion at 6 months, peripheral visual field defects did not re-
solve, and a new paracentral scotoma developed [7]. Our
patient had a similar presentation to this patient with
anterior uveitis and bilateral neuroretinitis. However, he
was treated with high-dose (1 mg/kg) oral corticosteroids
in addition to topical therapy with rapid control of inflam-
mation (1 month rather than 5 months) and restoration of
20/25 vision without optic nerve pallor. Ipilimumab ther-
apy was also discontinued, which may have also played a
role in his improved visual outcome.
Understanding the natural history and good response to
corticosteroids of most ipilimumab ocular irAEs is import-
ant for management, as discontinuation of ipilimumab
therapy is reserved for severe or life-threatening irAEs. Our
case, in conjunction with the summary of previously pub-
lished cases, suggests that ocular complications can be
managed with corticosteroid therapy if other systemic irAEs
do not require discontinuation of therapy. In the presence
of posterior uveitis or significant sight-threatening inflam-
mation, systemic corticosteroids should be considered and
can provide good visual recovery. Unfortunately, in the ma-
jority of the reported cases of ocular irAEs, the patients also
experienced other grade 3 or 4 systemic complications,
necessitating ipilimumab discontinuation.
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